Latest news with #Aleve
Time of India
2 days ago
- Health
- Time of India
Common painkillers can increase the risk of repeated heart attacks: Study
Many people reach for over-the-counter painkillers like Advil, Motrin, or Aleve without a second thought, assuming they are completely safe for everyday use. However, a 2012 study suggests that heart attack survivors may need to exercise caution when using these common medications. Published in the Journal Circulation , the research examined the effects of nonsteroidal anti-inflammatory drugs (NSAIDs) and found that they can significantly increase the risk of repeated heart attacks and even death among individuals with a history of cardiovascular disease. While NSAIDs are generally considered safe for occasional use at low to moderate doses, the study emphasizes that people who have experienced a heart attack should consult their doctors before taking these drugs. Understanding the risks and exploring safer alternatives can be crucial for long-term heart health What the study revealed about painkillers and repeated heart attack risk The research, conducted in Denmark, followed nearly 100,000 people who had survived a first heart attack, monitoring their health outcomes over five years. During that time, almost half were prescribed NSAIDs for pain relief. The results showed a striking pattern: those who took NSAIDs were about 60% more likely to die within the first year compared to people who avoided them. The study also highlighted that the use of these drugs increased the risk of experiencing another heart attack or serious cardiovascular complication. These findings underline the importance of long-term monitoring for heart patients who continue to use such medications after their initial recovery. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Buy Resmed AirSense 11 with flat 20% off ResMed Buy Now Undo Which painkillers pose the greatest risk Not all NSAIDs carry the same level of danger. The study found that diclofenac (sold under brand names like Voltaren and Cataflam) was linked to the highest rates of death and recurrent heart attacks, making it particularly concerning for people with cardiovascular conditions. Ibuprofen, one of the most widely used NSAIDs, also showed an elevated risk when taken regularly. In contrast, naproxen (found in Naprosyn and Aleve) appeared relatively safer and was associated with the lowest risk among NSAIDs. However, researchers stressed that 'lower risk' does not mean 'no risk.' Even naproxen should be used cautiously, and only under a doctor's guidance, especially in patients who already have heart problems. Why NSAIDs may be dangerous The biological reasons behind these risks are not fully understood, but researchers have put forward several explanations. One possibility is that patients taking NSAIDs may stop their daily low-dose aspirin, which is often prescribed after a heart attack to prevent clotting. Without aspirin's protective effects, the likelihood of another heart attack rises. Another theory is that NSAIDs themselves interfere with aspirin's ability to thin the blood, reducing its effectiveness against clot formation. Additionally, NSAIDs can increase blood pressure, cause fluid retention, and affect kidney function – all of which add stress to the cardiovascular system. This combination of factors likely contributes to the higher rates of recurrence and mortality seen in heart attack survivors who take these drugs. Safer alternatives for pain relief Given these risks, experts recommend that heart patients avoid NSAIDs unless absolutely necessary. The American Heart Association advises acetaminophen (Tylenol) as a safer alternative for mild to moderate pain because it does not carry the same cardiovascular risks. In cases where an NSAID must be used, doctors urge patients to take the lowest possible dose for the shortest amount of time. Timing also matters – if a patient is on both aspirin and an NSAID like ibuprofen, aspirin should be taken at least an hour beforehand to maintain its protective effect. Beyond medications, non-drug strategies such as physiotherapy, exercise, hot and cold therapy, or lifestyle adjustments may also help manage chronic pain without raising cardiovascular risk.
Time of India
13-08-2025
- Health
- Time of India
Kidney Damage from painkillers: What you need to know
Pain is common. Headaches, injuries, arthritis and chronic conditions put many people on pain medicine. For most, a pill eases the day. But some pain medicines can hurt the kidneys if used often or for a long time. Types of pain and common pain medicines Pain can be classified by how long it lasts and what causes it. Acute pain is short lived. It follows an injury, surgery, or a bad flu. Chronic pain lasts more than three months. It can come from arthritis, nerve damage, cancer, or long-term conditions. Many pain medicines are available. Some you can buy without a prescription (OTC). Others need a doctor's script. Common OTC medicines are acetaminophen (Tylenol) and nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen (Advil), naproxen (Aleve) and topical diclofenac (Voltaren gel). Prescription pain medicines include stronger NSAIDs, opioid drugs, certain antidepressants and anti-seizure medicines used for nerve pain, and corticosteroids. Some pills mix two or more drugs (for example, aspirin plus acetaminophen) or add caffeine or codeine. Those combination products are the most risky when taken daily for years. How painkillers can harm the kidneys Long-term use of some painkillers can injure the tiny blood vessels that filter waste in the kidneys. This slow damage is called analgesic nephropathy. NSAIDs are the main offenders. They reduce blood flow in the kidney and can cause acute kidney injury (AKI) or worsen chronic kidney disease (CKD). People who take high doses or use NSAIDs every day are at particular risk. Acetaminophen is generally safer for the kidneys when used at recommended doses. But many products contain acetaminophen plus other drugs. That raises the chance of accidental overdose or combined harms. Opioids do not directly poison kidney filters in the same way as NSAIDs, but some opioid drugs and their metabolites can build up in people with poor kidney function and cause side effects. Corticosteroids do not usually cause direct kidney injury, but they can raise blood pressure, cause fluid retention, and increase blood sugar, factors that stress the kidneys over time. Some painkillers also contain codeine or caffeine. Long-term use of combination pills seems linked to higher rates of kidney damage in several studies. That is why doctors warn against the daily use of multi-ingredient pain medicines for chronic pain. Who is at higher risk? Not everyone has the same risk. The people most vulnerable include those who already have kidney disease, those over middle age, people with heart disease or liver disease, those taking blood pressure medicines such as ACE inhibitors or ARBs or diuretics, people with autoimmune diseases like lupus, and those who drink heavily or become dehydrated. Even otherwise healthy people can develop problems if they take large doses for long periods. Symptoms of kidney damage from painkillers Kidney damage from painkillers can be silent at first. When symptoms appear, they may include fatigue, blood in the urine, more frequent urination, back or flank pain, nausea, swelling in the legs, and confusion. Doctors use blood tests, urine tests, imaging, and sometimes biopsies to diagnose the problem. The first step in treatment is to stop the offending medicines. Care may also include hydration, medication adjustments, dietary changes, and pain-management alternatives. The goal is to prevent further damage and treat any existing kidney failure.
Yahoo
17-04-2025
- Business
- Yahoo
Bayer Unveils $44 Million Investment in Myerstown, PA Manufacturing Facility, Renewing Commitment to U.S. Innovation, Health and Community
The facility's new space enhances the company's Consumer Health production capabilities, embraces automation, and invests in workforce development and community engagement MYERSTOWN, Pa., April 16, 2025--(BUSINESS WIRE)--Today, Bayer proudly celebrated the grand opening of its new 70,000 square foot expansion at its Myerstown facility, following a $44 million investment in 2022. This state-of-the-art facility is a testament to Bayer's commitment to providing trusted self-care solutions to consumers across North America while advancing meaningful engagement with the local community. The ribbon-cutting ceremony was attended by Bayer leaders, employees, elected officials, and members of the local community to commemorate this exciting moment for Bayer and Pennsylvania's Lebanon County. Bayer's Myerstown site has a rich history dating back over 75 years, and it has now grown to become the largest manufacturing site in Bayer's Consumer Health network globally, producing brands such as Bayer® Aspirin, Aleve®, Claritin®, One A Day®, Alka-Seltzer Plus®, Midol®, and more. "Our trusted brands have been helping people live healthier lives for generations. The Myerstown annex will enable us to bring science-backed products to market with more speed and reliability than ever before," stated Dave Tomasi, President of Bayer's Consumer Health division in North America. "The expanded facility will further strengthen our commitment to providing safe, effective and high-quality self-care solutions that our consumers and customers can depend on." Bayer's Myerstown facility is set to advance its production capabilities through the integration of modernized technology and streamlined processes, strengthening its ability to reliably deliver science-driven self-care solutions. The new space is designed to move products more efficiently with eight new product packaging lines and automated systems in logistics. With the expansion, Bayer is increasing its ability to swiftly respond to the evolving needs of its consumers and customers. Bayer's commitment to growth extends beyond infrastructure and technology; it is an investment in the future of health and wellness for consumers across North America and the people of Myerstown. Along with expanding its physical footprint, the company is dedicated to digitally upskilling its workforce to ensure that employees and the local community are equipped with the knowledge needed to navigate the modern manufacturing landscape. Bayer also plans to welcome local high school educators to tour its Myerstown facilities and operations to bring back information and insights to their school districts. "We recognize that the key to sustainable growth lies in our people. That's why we will enable our workforce with the skills needed to adapt to new technologies so they can excel in their careers," said Divakar Amin, Vice President & Site Manager of Myerstown. "We are proud to contribute to the local economy and foster a vibrant workforce made up of many Myerstown locals. Together, we are building a brighter future for Bayer and the communities we serve." As Bayer continues to innovate and empower everyday health, the company remains steadfast in its mission to elevate the quality of life for people around the world through trusted health and nutrition solutions. "Our commitment to credible science and consumer advocacy drives our mission Health for all, Hunger for none," said Michael Sullivan, Senior Vice President of Product Supply for Bayer's Consumer Health division in North America. "We are excited about the positive impact this investment will have as we are paving the way for a healthier future where everyone has access to the products that they need to support their well-being." About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, "Health for all, Hunger for none," the company's products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to View source version on Contacts Media Contact: Hannah SchwartzEmail: Cell: 862-783-8442 Sign in to access your portfolio
Yahoo
16-04-2025
- Business
- Yahoo
Bayer Unveils $44 Million Investment in Myerstown, PA Manufacturing Facility, Renewing Commitment to U.S. Innovation, Health and Community
The facility's new space enhances the company's Consumer Health production capabilities, embraces automation, and invests in workforce development and community engagement MYERSTOWN, Pa., April 16, 2025--(BUSINESS WIRE)--Today, Bayer proudly celebrated the grand opening of its new 70,000 square foot expansion at its Myerstown facility, following a $44 million investment in 2022. This state-of-the-art facility is a testament to Bayer's commitment to providing trusted self-care solutions to consumers across North America while advancing meaningful engagement with the local community. The ribbon-cutting ceremony was attended by Bayer leaders, employees, elected officials, and members of the local community to commemorate this exciting moment for Bayer and Pennsylvania's Lebanon County. Bayer's Myerstown site has a rich history dating back over 75 years, and it has now grown to become the largest manufacturing site in Bayer's Consumer Health network globally, producing brands such as Bayer® Aspirin, Aleve®, Claritin®, One A Day®, Alka-Seltzer Plus®, Midol®, and more. "Our trusted brands have been helping people live healthier lives for generations. The Myerstown annex will enable us to bring science-backed products to market with more speed and reliability than ever before," stated Dave Tomasi, President of Bayer's Consumer Health division in North America. "The expanded facility will further strengthen our commitment to providing safe, effective and high-quality self-care solutions that our consumers and customers can depend on." Bayer's Myerstown facility is set to advance its production capabilities through the integration of modernized technology and streamlined processes, strengthening its ability to reliably deliver science-driven self-care solutions. The new space is designed to move products more efficiently with eight new product packaging lines and automated systems in logistics. With the expansion, Bayer is increasing its ability to swiftly respond to the evolving needs of its consumers and customers. Bayer's commitment to growth extends beyond infrastructure and technology; it is an investment in the future of health and wellness for consumers across North America and the people of Myerstown. Along with expanding its physical footprint, the company is dedicated to digitally upskilling its workforce to ensure that employees and the local community are equipped with the knowledge needed to navigate the modern manufacturing landscape. Bayer also plans to welcome local high school educators to tour its Myerstown facilities and operations to bring back information and insights to their school districts. "We recognize that the key to sustainable growth lies in our people. That's why we will enable our workforce with the skills needed to adapt to new technologies so they can excel in their careers," said Divakar Amin, Vice President & Site Manager of Myerstown. "We are proud to contribute to the local economy and foster a vibrant workforce made up of many Myerstown locals. Together, we are building a brighter future for Bayer and the communities we serve." As Bayer continues to innovate and empower everyday health, the company remains steadfast in its mission to elevate the quality of life for people around the world through trusted health and nutrition solutions. "Our commitment to credible science and consumer advocacy drives our mission Health for all, Hunger for none," said Michael Sullivan, Senior Vice President of Product Supply for Bayer's Consumer Health division in North America. "We are excited about the positive impact this investment will have as we are paving the way for a healthier future where everyone has access to the products that they need to support their well-being." About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, "Health for all, Hunger for none," the company's products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to View source version on Contacts Media Contact: Hannah SchwartzEmail: Cell: 862-783-8442
USA Today
14-03-2025
- Health
- USA Today
Arson investigation launched after fire at Bayer executive's New Jersey home
Arson investigation launched after fire at Bayer executive's New Jersey home Show Caption Hide Caption Health insurance industry faces backlash after UnitedHealthcare CEO death There's a common theme in the wave of unsympathetic posts about UnitedHealth exec Brian Thompson's death: rage against the health insurance industry. PARSIPPANY, N.J. — Multiple federal and state agencies are investigating a possible arson attempt at the New Jersey home of an executive of global pharmaceutical giant Bayer, authorities said. Earlier this week, the Morris County Prosecutor's Office said a fire was reported around 7:30 a.m. on March 4 at an occupied residence in the borough of Madison. The suburban community is about 15 miles west of Newark, New Jersey. The prosecutor's office told the Morristown Daily Record, part of the USA TODAY Network, that Madison firefighters responded to the incident and that the fire was quickly extinguished. No significant property damage or injuries were reported. The prosecutor's office declined to identify the residents of the home, citing an "active and ongoing" arson investigation. Bayer spokesperson Nicole Hayes confirmed to the Daily Record that an incident occurred at the "private home of one of Bayer's U.S. executives," adding that the "family is safe and unharmed." "The safety and security of our employees are of utmost importance to Bayer," Hayes said. "The incident is under active investigation. The company is cooperating fully with the investigation. We appreciate the quick response of local law enforcement." Several agencies, including the Morris County Prosecutor's Office Arson/Environmental Crimes Unit, Morris County Sheriff's Office CSI Unit, New Jersey State Fire Marshals Office K-9 Unit, New Jersey Transit Police, the Metropolitan Transportation Authority Police Department, and the New York City Police Department are investigating the incident as a possible arson. On Thursday, the prosecutor's office told NBC News and CNN that the Federal Bureau of Investigation is also assisting in the investigation. The incident was first reported by Yahoo Finance last Friday. UnitedHealth CEO: 'We understand people's frustrations' with health care system What is Bayer? Bayer, an international pharmaceutical and biotechnology company, was founded in Germany in 1863. The company initially focused on manufacturing and selling synthetic dyestuffs, according to the Bayer website. It is now one of the world's largest pharmaceutical companies and known for making prescription drugs and other consumer health products such as aspirin, Alka-Seltzer, Claritin, and Aleve. Bayer consolidated its U.S. operations in 2013, opening a new $250 million headquarters in the Whippany section of Hanover Township, New Jersey. Former New Jersey Gov. Chris Christie, who approved a $35.1 million business incentive grant to keep the company in the state, attended the grand opening. In recent years, the company has been under intense scrutiny after it acquired Roundup under the $63 billion takeover of agrochemical company Monsanto in 2018. Roundup is a popular residential and commercial herbicide widely used by landscapers and agricultural workers. Reuters reported last Friday that Bayer told U.S. lawmakers it may halt the sales of Roundup if it does not receive stronger legal protections against product liability litigation. The company has faced thousands of lawsuits that claimed victims developed a form of non-Hodgkins lymphoma from exposure to glyphosate, which was the active ingredient in Roundup sold for home use until 2023, according to Reuters. Bayer has paid about $10 billion to settle disputed claims. About 67,000 cases are pending, for which the group has set aside $5.9 billion in legal provisions. 'Root cause of health care cost': UnitedHealth CEO remembers slain colleague, talks about health care woes Incident follows increased security measures for companies Last week's incident comes amid heightened security measures and social media vitriol aimed at the health insurance industry and corporate America. Authorities and companies feared potential attacks targeting industry executives after the shooting of UnitedHealthcare CEO Brian Thompson in December. Thompson, 50, was shot outside a New York City hotel while on his way to speak at an annual investor conference. Luigi Mangione, 26, was arrested following a massive manhunt and faces state charges of murder as an act of terrorism. He pleaded not guilty in December. The shooting sparked an outpour of contempt toward health insurers with people on social media sharing their grievances over denied claims and complaints about perceived greed in the industry. In the immediate aftermath of the incident, videos posted online appeared to show "wanted" posters in New York with the names and faces of other corporate executives. Thompson's death prompted industry peers to remove biographies and photographs of top executives from their websites. Some companies also closed offices or canceled in-person events. "It was an eye-opening experience for many CEOs. ... Most of them think they're anonymous. A great deal of them, they drive themselves to work or just jump in a cab," Matthew Peters, vice president of protective services at security provider Guidepost Solutions, previously told USA TODAY. Contributing: Bailey Schulz, Ken Alltucker, Jeanine Santucci, and N'dea Yancey-Bragg, USA TODAY; Reuters
